Lv6
2120 积分 2025-01-05 加入
Long-Term Outcomes in IgA Nephropathy
3天前
已完结
Long-term outcomes of IgA nephropathy in China
3天前
已完结
Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study
16天前
已完结
Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?
1个月前
已完结
Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial
1个月前
已完结
Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?
1个月前
已完结
Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population
1个月前
已关闭
Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol
1个月前
已完结
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach
1个月前
已完结
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
1个月前
已完结
皖公网安备34019202002308
